Last reviewed · How we verify
COVID-19 mRNA vaccine
The vaccine delivers mRNA encoding the SARS-CoV-2 spike protein, which is translated by host cells to trigger adaptive immune responses against COVID-19.
The vaccine delivers mRNA encoding the SARS-CoV-2 spike protein, which is translated by host cells to trigger adaptive immune responses against COVID-19. Used for Prevention of COVID-19 in adults and children, Booster vaccination for enhanced protection against emerging variants.
At a glance
| Generic name | COVID-19 mRNA vaccine |
|---|---|
| Sponsor | Vaccine Company, Inc. |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein (S protein) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The mRNA is encapsulated in lipid nanoparticles for cellular delivery. Once inside cells, the mRNA is translated into spike protein antigen, which activates both CD8+ T-cell and B-cell responses, generating antibodies and cellular immunity against SARS-CoV-2. This approach bypasses the need for live virus and enables rapid manufacturing.
Approved indications
- Prevention of COVID-19 in adults and children
- Booster vaccination for enhanced protection against emerging variants
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
- Chills
- Nausea
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
- Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
- Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COVID-19 mRNA vaccine CI brief — competitive landscape report
- COVID-19 mRNA vaccine updates RSS · CI watch RSS
- Vaccine Company, Inc. portfolio CI